SEC Form SC 13G filed by Centessa Pharmaceuticals plc
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/28/2025 | $35.00 | Overweight | Stephens |
| 9/3/2025 | $31.00 | Overweight | Wells Fargo |
| 8/29/2025 | $40.00 | Outperform | Oppenheimer |
| 7/21/2025 | $30.00 | Buy | Truist |
| 5/28/2025 | $35.00 | Buy | Needham |
| 5/8/2025 | $30.00 | Buy | Chardan Capital Markets |
| 3/31/2025 | $38.00 | Overweight | Piper Sandler |
| 1/7/2025 | Buy | TD Cowen |
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
Stephens initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $35.00
Wells Fargo initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $31.00
Oppenheimer resumed coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $40.00
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
SCHEDULE 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)
SCHEDULE 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about November 14, 2025, subject to customary closing conditio
BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies, Le
BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in LondonDate: Tuesday, November 18, 2025Fireside Chat: 2:00 PM GMT/ 9:00 AM ET Event: 37th Annual Piper Sandler Healthcare ConferenceDate: Tuesday, December 2, 2025Fireside Chat: 3:00 PM ET Event: 8th Annu
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advancing in IND-enabling studies; Expect to initiate clinical studies in Q1 2026 BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmace
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cent
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)